Curcumin nudged up adiponectin across six pooled trials

Adiponectin is a hormone that researchers routinely measure when they study metabolic health, and finding ways to raise it has become a recurring question in nutrition science. Curcumin is one of the most heavily marketed supplement compounds, with individual trials reporting mixed effects on a range of blood markers. Small single trials can easily point in different directions, so pooling them is the only way to see whether curcumin has any consistent effect on this particular hormone. That is the question this review set out to answer.

The researchers searched five major research databases, including PubMed, Scopus and the Cochrane Library, for studies published up to April 2019. They looked specifically for trials in adults where people were randomly assigned to curcumin or a comparison group, and where blood adiponectin was measured as an outcome. From 313 records identified in the search, 6 trials met the criteria, together enrolling 652 people. The team then pooled the change in adiponectin across those trials using a statistical approach that allows for differences between studies.

Curcumin supplementation significantly increased adiponectin concentrations compared with placebo across the pooled trials. In statistical terms the effect was 0.82 on the Hedges' g scale, a standardised measure of effect, with the plausible range running from 0.33 to 1.30. Interestingly, the effect appeared greater in trials lasting 10 weeks or less, where the pooled figure rose to 1.05. The authors were careful to note limitations in the evidence and concluded that further studies are needed before a definitive conclusion can be reached.

This is a first line of pooled evidence suggesting curcumin can shift adiponectin, which strengthens the case beyond any single trial. But six trials is a slim foundation, and the finding that shorter trials showed bigger effects is puzzling: if the hormone rise were durable, longer supplementation would be expected to show at least as much. The review measured a blood marker, not a health outcome, so whether the change matters for disease risk remains open. The authors themselves call for more research before firm conclusions.

If you already take curcumin, this is evidence that it may be doing something measurable to one hormone in your blood. What it is not, at this stage, is evidence of any health benefit: no outcome such as weight, blood sugar control or disease risk was assessed here. The sensible reading is that curcumin's effect on adiponectin looks real in pooled trial data but limited in scope, and the authors' own caution is worth taking at face value. This is a marker worth watching rather than a reason to change anything.